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ABSTRACT
Magnetic nanoparticles have properties that cause to apply them in cancer therapy and vehicles for the
delivery of drugs such as 5FU, especially when they are modified with biocompatible copolymers. The
aim of this study is to modify superparamagnetic iron oxide nanoparticles (SPIONPs) with PCL–PEG–PCL
copolymers and then utilization of these nanoparticles for encapsulation of anticancer drug 5FU. The
ring-opening polymerization (ROP) was used for the synthesis of PCL–PEG–PCL copolymer by e-capro-
lactone (PCL) and polyethylene glycol (PEG2000). We used the double emulsion method (water/oil/
water) to prepare 5FU-encapsulated Fe3O4 magnetic nanoparticles modified with PCL–PEG–PCL copoly-
mer. Chemical structure and magnetic properties of 5FU-loaded magnetic-polymer nanoparticles were
investigated systematically by employing FT-IR, XRD, VSM and SEM techniques. In vitro release profile of
5FU-loaded NPs was also determined. The results showed that the encapsulation efficiency value for
nanoparticles were 90%. Moreover, the release of 5FU is significantly higher at pH 5.8 compared to pH
7.4. Therefore, these nanoparticles have sustained release and can apply for cancer therapy.
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Introduction
Drug delivery systems have some drawbacks. For example,
oral drug delivery systems that are extremely important to
the field of medicine, because the largest part of the com-
mon illnesses is treated by oral rout of medication, they have
some defects such as low solubility in aqueous solutions and
low penetration across intestinal membranes [1]. The gastro-
intestinal system has problems for protein drug delivery. Also
cancer chemotherapeutics due to their nonselective activity
are less effective to cure tumours so resulting in dose limiting
side effects [2,3].
Drug delivery systems have modified with new therapeutic
molecules such as nucleic acids, peptides and others to
improve themselves. Moreover, some of these systems give a
stable concentration of drug in the bloodstream for a long
period of time that is attractive for the treatment of some dis-
eases, and there is factual evidence of patients’ indicating
improvement during this treatment [4]. Drug delivery with con-
trolled rate, sustain release and targeted delivery are other very
attractive ways and have been pursued remarkably [5,6].
Recent progresses in the applying of carriers for sustain
and target drug delivery, micro- and nano-systems [7,8], bio-
recognizable structures, micro-needles for transdermal drug
delivery lead to improve permeability and flexibility of these
polymeric materials. In the smart drug delivery systems,
micro- and nanoparticles can hold and release diverse active
agents on demand [9]. The main purposes of nanoparticles in
a drug delivery system are controlling: surface properties, par-
ticle size and release of pharmacologically active ingredients
in the way to get the drug at the targeted site in the optimal
rate and dose procedure [10,11]. Systems based on drug
delivery can provide improved efficacy and decreased toxicity
for anticancer agents. Long blood circulation result in carriers
can use the “enhanced permeability and retention” (EPR)
effect for special extravasation from tumour vessels [12].
Drug-loaded nanoparticles transport therapeutics to tumour
sites undergo a multistep process to achieve their therapeutic
target, launch with extravasation from leaky tumour vessels
[13] (see Figure 1).
Various nanosystems have been studied as drug delivery
systems such as polymeric micelles, polymeric nanoparticles,
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nanogels, nanocapsules, fullerenes, solid lipid nanoparticles
(SLN), nanoliposomes, dendrimers, quantum dots and metal
nanoparticles [6,14]. Magnetic nanoparticles (MNPs) have
received much attention due to their unique physical proper-
ties, biocompatibility, magnetic susceptibility, stability and
their role in the cellular and molecular level of biological
interactions. In addition, MNPs are easily controlled by an
exterior magnetic field application, which offer the releasing
of the anticancer agent at an exact rate and at a specific site,
overcoming the problems of conformist techniques for diag-
nosis and therapy. These properties cause the magnetic
nanoparticles be suitable in biomedical fields, such as, drug
delivery, hyperthermia treatment [15–17].
Polymeric nanoparticles have benefits for drug delivery
such as encapsulation of bioactive molecules and protection
them from enzymatic and hydrolytic degradation [6,18–21].
Therapeutically polymeric nanoparticles that used are com-
posed of biocompatible or biodegradable materials, like pol-
y(lactic-co-glycolic acid) (PLGA), poly(lactic acid) (PLA), poly(e-
caprolactone) (PCL), alginic acid, chitosan and gelatin [22–26].
Specially, amphiphilic, thermosensitive ones for example BAB
and ABA tri-block or AB di-block consisting of hydrophobic
(B) and hydrophilic (A) blocks have been researched more
than other smart systems because of their in situ gel-forming
properties at body temperature [27–29]. Polycaprolactone
(PCL) is a hydrophobic, biodegradable, semi-crystalline poly-
mer. The suitable solubility of this polymer, its low melting
point and amazing blend-compatibility have encouraged wide
studies into its possible uses in the biomedical field like packag-
ing, medical implant, and controlled drug delivery [30,31].
The purpose of this work was to evaluate the magnetic-
PCL–PEG–PCL nanoparticles as anticancer drug carriers.
Firstly, Fe3O4 magnetic nanoparticles were prepared and then
the PCL1000–PEG2000–PCL1000 triblock copolymer was synthe-
sized with ring opening polymerization by e-caprolactone
and PEG and stannous octoate as catalyst [32]. Then, 5FU was
encapsulated in Fe3O4–PCL–PEG–PCL nanoparticles by the
double emulsion method (w/o/w). The physicochemical prop-
erties of nanoparticles and in vitro release of 5FU were char-
acterized [33–38].
Experimental section
Materials and methods
Ferric chloride hexahydrate (FeCl36H2O), ferrous chloride tet-
rahydrate (FeCl24H2O) and ammonium hydroxide (32wt.%)
were purchased from Fluka (Buchs, Switzerland).
e-Caprolactone (e-Cl)), stannous octoate (Sn(Oct)2) and poly-
ethylene glycol (PEG) (molecular weight 2000) were pur-
chased from Sigma Aldrich (St. Louis, MO). Infrared spectra
were recorded with BRUKER series FTIR. The magnetic prop-
erty was measured on a vibrating sample magnetometer
(Meghnatis Daghigh Kavir, Iran) at a maximum magnetic field
of 10 kOe at room temperature [39]. X-ray diffraction and
scanning electron microscopy (SEM) measurements were con-
ducted using VEGA and TESCAN, respectively. The drug
Figure 1. Image of multivalent targeting in nanoparticle drug delivery [13].
Figure 2. Preparation of magnetic nanoparticles.
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encapsulation efficiency and release profile were determined by
an ultra violet visible spectrometer (Shimadzu, Tokyo, Japan).
Preparation of superparamagnetic nanoparticles
Chemical coprecipitation method was used for the synthesis of
magnetic nanoparticles [40]. Giving to this method, 0.7418 g of
FeCl24H2O (4mmol) and 0.2242 g of FeCl36H2O (7mmol) were
dissolved in 10ml of deionized water, such that the ratio of
Fe2þ/Fe3 þ was 1.75:1, respectively. This solution was stirred
under nitrogen at 85 C for 1 h. In the next step, 22.5ml NH3H2O
(25%) was added into the solution quickly, stirred under nitro-
gen for 1 h, and then cooled at room temperature. Finally, the
precipitated particles were washed three times with water and
dried under vacuum at 70 C (see Figure 2).
Synthesis of (PCL1000–PEG2000–PCL1000) triblock
copolymer
PCL1000–PEG2000–PCL1000 copolymer was prepared by ring
opening polymerization. Sn(Oct)2 was a catalyst of reaction. A
7.4 g of e-caproate lactone and 5 g of polyethylene glycol
with a molecular weight of 2000 (PEG2000) were weighed and
in a bottleneck flask were heated to 120 C under a nitrogen
atmosphere to complete melting. Then 1ml of 0.05% (w/w)
stannous octoate was added and the temperature was raised
to 130 C. This temperature was continued for 2 h. The poly-
merization was carried out under vacuum [41].
Preparation of 5FU encapsulated Fe3O4 magnetic
nanoparticles modified with PCL–PEG–PCL copolymer
We used double emulsion method (water/oil/water) for
encapsulation of 5FU in Fe3O4–PCL–PEG–PCL modified nano-
particles. Firstly, an aqueous solution of 5FU (2.5mg/2.5ml)
was added to dichloromethane, that 120mg of the
PCL–PEG–PCL copolymer and 5mg of the Fe3O4 nanoparticles
had been dissolved in it, using a sonication at 20,000 rpm for
25 s, the w/o emulsion was created. Then w/o emulsion was
added to a 50ml aqueous solution of PVA (polyvinyl alcohol)
0.5% and the mixture was sonicated at 70,000 rpm for 2min
to make w/o/w emulsion. The w/o/w emulsion was stirred at
room temperature to evaporate the organic phase (Heidolph
Instruments, Hei-VAP Series, Schwabach, Germany). In order
to purify the nanoparticles, two cycles of centrifugation
(10,000 rpm for 1 h in a Biofuge 28 RS, Heraeus centrifuge)
was used. Then the precipitate and solution were separated.
Nanoparticles was dried by freeze-drying and supernatant
solution was used to measure the concentration of encapsu-
lated drug. Finally, the nanoparticles were filtered through a
1.2mm filter (Millipore, Bedford, MA). To determine the
encapsulation efficiency of 5FU in modified Fe3O4 magnetic
nanoparticles, nanoparticles were disintegrated in dichloro-
methane [42]. The 5FU concentration was determined by
spectrophotometer at 266 nm. Drug encapsulation efficiency
was obtained with the following equation:
Encapsulation efficiency ð%Þ
¼ ðDrug total – Drug supernatantÞ=Drug total 100
Nanoparticle characterization
FTIR spectrophotometer (BRUKER series) was used for record-
ing infrared spectra. For this purpose, the samples and KBr
were pressed to form a tablet. In order to analysis the crystal
structure of the Fe3O4 magnetic nanoparticles, power X-ray
diffraction (Rigaku D/MAX-2400 X-ray diffractometer) was
applied. The magnetization curves of the samples were meas-
ured by vibrating sample magnetometry at room tempera-
ture. To determine the size and morphology of the
nanoparticles, SEM was used by VEGA/TESCAN.
In vitro drug release profile study
For this purpose, 3mg of 5FU-encapsulated modified mag-
netic nanoparticles was dispersed in 30ml of phosphate buf-
fered solution (pH 7.4). Samples were incubated in 37 C.
Figure 3. Fourier transform infrared spectra of magnetic nanoparticles.
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In determined time intervals, 3ml of samples were removed
and analyzed with ultraviolet spectrofluorometry (Shimadzu,
Tokyo, Japan) and same volume of fresh phosphate-buf-
fered solution was reconstituted. The samples were ana-
lyzed with ultraviolet spectrofluorometry to calculate the
amount of released 5FU (kex 470 nm and kem 585 nm). To
investigate the effect of pH on drug release, the test was
repeated in acidic acetate buffer solution (pH ¼8.5) and at
temperature 40 C.
Results and discussion
Characterization of nanoparticles
The encapsulation efficiency value achieved for 5FU was:
EE% ¼ ðDrug total – Drug supernatantÞ=Drug total  100
EE % ¼ 5 0:382ð Þ=5   100 ¼ 90%
FTIR spectroscopy
The structure confirmation of Fe3O4 and PCL–PEG–PCL
copolymer was studied by FTIR spectroscopy. From the infra-
red spectra shown in Figure 3, the absorption peaks at
580 cm1 belonged to the stretching vibration mode of Fe–O
bonds in Fe3O4, 3402 cm
1 belonged to free hydroxyl group
(OH) of Fe3O4. The peaks at 2869 cm
1 and 2950 cm1 are
due to C–H stretch. Absorption at 933 cm1 and 1247 cm1
belonged to C–O stretch. 1750–1765 cm1 is assigned to
C¼O, 1090–1300 cm1 assigned to C–C, C–O and
1085–1150 cm1 is due to polyethylene glycol ether band
(see Figures 4 and 5).
X-ray diffraction patterns
The X-ray diffraction was used to study the crystal structure
of the Fe3O4 nanoparticles. This provides patterns for pure
Fe3O4 magnetic nanoparticles and 5FU-encapsulated modified
magnetic nanoparticles. The characteristic diffraction peaks
are indicated, respectively, by their indices (2 2 0), (3 1 1),
(4 0 0), (4 2 2), (5 1 1) and (4 4 0), which could be well indexed
to the inverse cubic spinel structure of Fe3O4 (JCPDS card 85-
1436). Characteristic diffraction peaks were also observed for
5FU-encapsulated Fe3O4 magnetic nanoparticles modified
with PCL–PEG–PCL copolymer. This determines that modifica-
tion of the Fe3O4 nanoparticles did not lead to any crystal
phase change. The average crystallite size D was about 10 nm
and obtained from the Sherrer equation Dkk¼ 0.9k (bCosh)
where K is the constant, k is the X-ray wavelength and b is
the peak width of half-maximum (see Figures 6 and 7).
Magnetic properties
The magnetic properties of Fe3O4 nanoparticles were deter-
mined with VSM at room temperature. Figure 8 displays the
hysteresis loops of the samples. For 5FU-encapsulated Fe3O4
magnetic nanoparticles modified with copolymer, the satur-
ation magnetization is 18 emu/g, which is less than the pure
Fe3O4 nanoparticles (61 emu/g). This difference recommends
that a large amount of copolymer modified magnetic nano-
particles and 5FU. It is possible to separate 5FU-encapsulated
modified Fe3O4 nanoparticles from the reaction medium by
using a magnetic field. This is due to the large saturation
magnetization. In addition, there was no hysteresis in the
magnetization, with both remanence and coercivity being
zero, indicating that these magnetic nanoparticles have
superparamagnetic properties [43].
Figure 4. Fourier transform infrared spectra of 5FU encapsulated Fe3O4 magnetic nanoparticles modified with PCL–PEG–PCL copolymer.
ARTIFICIAL CELLS, NANOMEDICINE, AND BIOTECHNOLOGY S941
SEM analysis
The size and surface morphology of the nanoparticles was
observed by SEM. Figure 9(a,b) shows micrographs of pure
Fe3O4 nanoparticles and 5FU-encapsulated Fe3O4 modified
nanoparticles, respectively. As it can be seen, the photograph
demonstrates that nanoparticles are well aggregated, which
was due to the nanosize of the Fe3O4 of about 10 nm. After
modification of magnetic nanoparticles with PCL–PEG–PCL
copolymer and encapsulation of 5FU, the size of the particles
changed, and dispersion of the particles was greatly
improved (Figure 9(b)), which can be due the electrostatic
repulsion force and steric hindrance between the copolymer
chains on the encapsulated Fe3O4 nanoparticles.
In vitro drug release profile
The release profiles of 5FU were achieved by the ratio of 5FU
release with respect to the total amount of 5FU encapsulated.
Releasing 5FU from nanoparticles has two phases: burst
release in initial and sustain release after 12 h. A major
amount of drug released within 12 h. This was 33.1% for
Fe3O4 magnetic nanoparticles modified with PCL–PEG–PCL
(Figure 10). The total release amount of 5FU over 2 days was
81.4% from Fe3O4–PCL–PEG–PCL. The 5FU release rate from
the Fe3O4–PCL–PEG–PCL nanoparticles was also pH-depend-
ent and improved at pH 5.8. In a drug releasing, several proc-
esses are involvement, containing distribution through the
polymer matrix, release by polymer degradation, and
Figure 6. XRD spectra of Fe3O4 magnetic nanoparticles.
Figure 5. (a) Fourier transform infrared spectra of PCL–PEG–PCL copolymer. (b) Comparative Fourier transform infrared spectra of synthesized copolymer
(PCL–PEG–PCL) with FT-IR spectra of its polymers.
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solubilization and diffusion through microchannels that exist
in the polymer matrix or are formed by erosion [44,45]).
Conclusion
Nanotechnology-based drug delivery can modify cancer treat-
ment by improving distribution and accumulation of several
drugs in the disease sites. Targeted drug delivery in cancer
by hyperthermia via magnetic nanoparticles has functional
characteristics such as small size, low toxicity, high stability,
simple purification and sterilization [46–49]. In this work, we
encapsulated 5FU in an improved and less-toxic carrier. In
order to minimize undesired uptake or interactions in unusual
sites, a biodegradable nanocarrier based on magnetic
nanoparticles and copolymer has been developed for 5FU.
Quantity and location of drug release are controlled by the
PCL–PEG–PCL-coated magnetic nanoparticles and pH. This
nanosystem can be used for targeting a wide variety of solid
tumours. There are some parameters that effect on encapsu-
lation efficiency such as copolymer concentration in organic
solution, volume of the outer aqueous phase, volume of the
internal aqueous phase, 5FU concentration in the inner aque-
ous phase, the first and second homogenized speed and
time. The encapsulation efficiency (EE) was 90%. It is indi-
cated that the 5FU-encapsulated Fe3O4–PCL–PEG–PCL nano-
particles have pH sensitive property and can be used for
targeting extracellular pH of cancer cells and could be an
effective carrier for anticancer drugs delivery.
Figure 7. XRD spectra of PCL1000–PEG2000–PCL1000 copolymer.
Figure 8. Magnetic behaviour of magnetic nanoparticles.
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Overall, modification of the magnetic nanoparticles could be
possible useful for drug delivery systems. Our results explain
that Fe3O4 magnetic nanoparticles modified with
PCL–PEG–PCL could be a valuable carrier for drug delivery.
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